VEEV News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

VE

Mkt Cap

$50.27B

Volume

1.39M

Next Earnings

November 19th

Loading chart

VE

VEEVVeeva Systems Inc.

VEEV

Pay with—

Available Balance0.00

VE

Mkt Cap

$50.25B

Volume

1.39M

Next Earnings

November 19th

Chart Financials Earnings News About Insider Filings

Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should KnowVeeva Systems (VEEV), a cloud-based software provider for the life sciences industry, has outperformed the broader market with a +12.3% return over the past month. The company shows strong earnings growth of +14.2% year-over-year for the current quarter and consistent revenue growth of +15.1%. However, with a Zacks Rank #3 (Hold) rating and a D valuation grade indicating premium pricing relative to peers, the stock is expected to perform in line with the broader market in the near term.Zacks Investment Research · Oct 15, 2026

iOnctura appoints Paul Sekhri as Chair of its Board of DirectorsiOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization. The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.GlobeNewswire Inc. · Oct 15, 2026

VEEV Expands IQVIA Partnership With Clinical Operations Software SuiteVeeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.Zacks Investment Research · Oct 14, 2026

Veeva Systems (VEEV) Increases Despite Market Slip: Here's What You Need to KnowVeeva Systems closed at $301.63, up 1.95% and outperforming the broader market decline. The stock has gained 11.36% over the past month, significantly outpacing the Medical sector's 1.06% gain. Upcoming earnings are expected to show 14.22% EPS growth and 15.11% revenue growth quarter-over-quarter, with full-year projections of $9.22 EPS and $3.69 billion revenue. The company holds a Zacks Rank of #3 (Hold) with a Forward P/E of 32.09, trading in line with its industry average.Zacks Investment Research · Oct 13, 2026

Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech FirmsVeeva Systems announced that over 175 emerging biotech companies are adopting Veeva Basics to streamline drug development operations. The pre-configured platform helps smaller biotechs establish technology infrastructure for clinical, regulatory, and quality processes. Growing adoption could support long-term revenue growth as these companies expand, though financial impact depends on customer retention and conversion to meaningful revenue.Zacks Investment Research · Oct 13, 2026

Reasons to Hold Veeva Systems Stock in Your Portfolio for NowVeeva Systems (VEEV) delivered strong Q2 fiscal 2027 results, beating estimates and raising its full-year outlook, driven by expanding Vault CRM adoption with 12 of top 20 biopharmas committed and over 180 customers live. The company is advancing AI initiatives with Veeva Falcon attracting early adopters. However, market saturation in the life sciences CRM space and intensifying competition from traditional and AI-powered platforms could constrain future growth rates.Zacks Investment Research · Oct 9, 2026

Global Decentralized Clinical Trials Market Size, Trends, and Forecast, 2025-2030 | AI, Wearables, and Cloud-Based Platforms Fuel 13.7% CAGR to $18.8 BillionThe global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.GlobeNewswire Inc. · Oct 9, 2026

Veeva's DQS Scales Data Automation Across 1,000+ Clinical StudiesVeeva Systems' Data Quality System (DQS) platform has expanded its reach to support data cleaning across over 1,000 clinical studies involving more than 1 million subjects, generating 500,000+ automated queries. The platform's integration with AI, CTMS, and Study Builder Agent is expected to drive deeper customer engagement and recurring revenue growth in the life sciences software market.Zacks Investment Research · Oct 7, 2026

Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?The VanEck Morningstar Wide Moat ETF (MOAT) is a smart beta ETF launched in 2012 that tracks companies with sustainable competitive advantages. With $11.46 billion in assets and a 0.46% expense ratio, it offers medium-risk exposure primarily to Information Technology, Healthcare, and Consumer Staples sectors. Year-to-date returns are 4.06% with a 7.97% one-year return. The article compares it to lower-cost alternatives like IVV and VOO, which track the S&P 500 with 0.03% expense ratios.Zacks Investment Research · Oct 6, 2026

Company News for Oct 5, 2026Nike shares fell 3.6% after missing Q4 fiscal 2026 revenue estimates with $11.21 billion in sales. Synaptics surged 14.1% following ON Semiconductor's revised $5.7 billion acquisition terms. NVIDIA rose 1.3% after reaching a new all-time intraday high of $237.87. Veeva Systems declined 3.1% as healthcare emerged as a losing sector.Zacks Investment Research · Oct 5, 2026

to start trading

VE

VEEVVeeva Systems Inc.

VEEV

Pay with—

Available Balance0.00

Your PositionYou don't own any VEEV yet.

Related Tickers

Earnings